Bio Medica Laboratories IPO Set to Launch on May 21: Everything You Need to Know!
Bio Medica Laboratories, incorporated in 2015, is preparing for its IPO scheduled from May 21 to May 25, 2026. The company specializes in the manufacturing of pharmaceutical parenteral formulations, particularly liquid and dry powder injectables for both human and veterinary applications. With a substantial product portfolio that includes 58 liquid injectables and 15 dry powder injectables, the company has reported a total installed manufacturing capacity of 5.70 crore ampoules and 1.65 crore vials as of FY 2025. The IPO consists of a fresh issue of 33,95,000 shares and an offer for sale of 3,77,000 shares, resulting in a total size of 37,72,000 shares. The face value per share is INR 10, and individual investors can anticipate allocation details on May 26, 2026.
The grey market sentiment for Bio Medica Laboratories is currently awaited, as the initial pricing information has not yet been disclosed. Observers in the capital market are keen on analyzing the Grey Market Premium (GMP) once the details are made available. Understanding this sentiment will be crucial for potential investors to gauge market expectations and sentiment leading up to the IPO. Furthermore, with the company’s financials indicating an increase in net income from INR 0.33 crore in FY 2023 to an anticipated INR 9.80 crore in FY 2025, investor confidence could be bolstered if the GMP reflects a favorable outlook.
For Indian investors, the Bio Medica Laboratories IPO presents an intriguing opportunity in the healthcare sector, which has garnered significant attention post-pandemic. With robust growth projections and a dedicated product portfolio, the IPO could attract institutional and retail participation, especially if the GMP suggests strong demand. As investors prepare for the IPO, they should monitor updates on the GMP and assess the overall market sentiment, which will be pivotal in making informed investment decisions in the upcoming listing.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova IPO team.)